Sign in

Pain neurobiology: nociceptors, channels and central sensitization

Background concepts · G1a · Reviewed by a board-certified pain physician on October 31, 2026

Bottom line

Nociception starts at channels such as Nav1.7 and TRPV1 and is amplified centrally; central sensitization explains allodynia and secondary hyperalgesia, and its mechanisms, like spinal immune signaling, can differ between sexes.

Key points

  1. Nav1.7 sets nociceptor excitability. Biallelic loss-of-function SCN9A mutations abolish Nav1.7 current and cause congenital inability to experience pain in otherwise healthy people 1; gain-of-function variants cause primary erythermalgia, burning red extremities 2.
  2. Nav1.7 also serves smell. It is required for synaptic signaling from olfactory sensory neurons, so Nav1.7-null patients are anosmic 3.
  3. CIPA is a different gene. Congenital insensitivity to pain with anhidrosis results from TRKA (NGF receptor) mutations and adds anhidrosis, unexplained fevers, self-mutilation and intellectual disability; it is autosomal recessive 4.
  4. TRPV1 explains capsaicin. High-concentration capsaicin activates TRPV1 on cutaneous nociceptors, causing burning, then reduces TRPV1-expressing nerve endings, which re-emerge over months 5.
  5. Central sensitization is CNS amplification. Woolf defines it operationally as amplified neural signaling within the CNS that elicits pain hypersensitivity: lower thresholds (allodynia), heightened responses (hyperalgesia) and receptive-field expansion (secondary hyperalgesia) 6.
  6. Spinal immune mechanisms differ by sex. In mice, microglia were required for nerve-injury hypersensitivity in males, whereas females relied on adaptive immune cells, likely T cells; microglia-targeting drugs worked only in males 7.

Watch for

Peripheral sensitization cannot account for dynamic tactile allodynia, temporal summation or secondary hyperalgesia; these point to central mechanisms, including pain that continues after the stimulus ends and spreads beyond the injury 6.

High-yield for the exam

  • Windup is a progressive rise in dorsal horn output during a train of identical C-fiber stimuli, first described by Mendell and Wall in 1965 6.
  • Central sensitization outlasts the conditioning input, persisting tens of minutes after it ends, unlike windup 6.
  • Ketamine inhibits central temporal summation and secondary mechanical hyperalgesia, supporting an NMDA receptor role 6.
  • Intradermal capsaicin produces tactile allodynia and secondary hyperalgesia used as a human model of central sensitization 6.
  • Capsaicin 8% treatment is not repeated more often than every 3 months 5.
  • Congenital inability to experience pain from SCN9A is autosomal recessive; primary erythermalgia from SCN9A is autosomal dominant 12.
  • Cox's families carried homozygous nonsense SCN9A mutations; mutant channels gave currents no greater than background 1.
  • Sorge and colleagues concluded that male animals cannot serve as proxies for females in pain research 7.

Numbers to know

Item Value
SCN9A protein Nav1.7 1
CIPA gene TRKA, the NGF receptor 4
Windup described 1965 6
Woolf's central sensitization study 1983 6
Conditioning burst in Woolf's model ~10–20 seconds at 1–10 Hz 6
Capsaicin 8% repeat interval ≥3 months 5
Cox families with SCN9A loss 3 consanguineous families, northern Pakistan 1

Common traps

  • Confusing Nav1.7 loss of function with CIPA; sweating and cognition are normal with Nav1.7 loss 14.
  • Equating windup with central sensitization 6.
  • Expecting an NMDA antagonist to dampen central sensitization without psychotomimetic effects; trials show little therapeutic index 6.
  • Assuming a target validated only in male animals will work in women 7.

Practise this topic

5 more questions on this topic in the full question bank, with explanations and sources.

Sources

  1. Cox JJ, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature, 2006. pmc.ncbi.nlm.nih.gov/articles/PMC7212082/
  2. Yang Y, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet, 2004. pubmed.ncbi.nlm.nih.gov/14985375/
  3. Weiss J, et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature, 2011. pmc.ncbi.nlm.nih.gov/articles/PMC3674497/
  4. Indo Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet, 1996. pubmed.ncbi.nlm.nih.gov/8696348/
  5. US Food and Drug Administration. QUTENZA (capsaicin) 8% topical system prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad
  6. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain, 2011. pmc.ncbi.nlm.nih.gov/articles/PMC3268359/
  7. Sorge RE, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci, 2015. pmc.ncbi.nlm.nih.gov/articles/PMC4772157/

Related topics

Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.